Menu
Recruiting NCT07241533

Asiaticoside for Treating Overweight/Obesity

No phase Interventional Overweight , Obesity

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Asiaticoside tablets.
Who it may be relevant to
Registry conditions: Overweight , Obesity. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
China
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

A Clinical Efficacy Study of Asiaticoside for Treating Overweight/Obesity

Overview

Centella asiatica is a traditional herbal medicine widely used in China and Southeast Asia for treating various conditions. Preclinical studies have shown that madecassic acid glycosides, including asiaticoside and madecassoside, can significantly reduce body weight gain, adipose tissue mass, and serum triglyceride levels in high-fat diet-induced obese mice. These compounds also improve hepatic steatosis and insulin resistance. This exploratory, interventional study aims to evaluate the clinical efficacy of orally administered asiaticoside tablets in adults with overweight or obesity.

Interventions

  • Drug Asiaticoside tablets
    Asiaticoside tablets 60mg tid for 12 weeks

Primary outcome measures

  • Change in Metabolic Rate [Time frame: Baseline to Week 4]
  • Change in Body Weight [Time frame: Baseline to Week 12]
Secondary outcome measures (11)
  • Change in Body Mass Index (BMI) [Time frame: Baseline to Week 12]
  • Change in Body Fat Percentage [Time frame: Baseline to Week 12]
  • Change in waist circumference [Time frame: From baseline to Week 12]
  • Change in Blood Pressure [Time frame: Baseline to Week 12]
  • Change in Lipid profile [Time frame: Baseline to Week 12]
  • Change in HbA1c [Time frame: Baseline to Week 12]
  • Change in Insulin Sensitivity (HOMA-IR) [Time frame: Baseline to Week 12]
  • Change in Leptin Levels [Time frame: Baseline to Week 12]
  • Change in High-Sensitivity C-Reactive Protein (hs-CRP) [Time frame: Baseline to Week 12]
  • Change in Liver Fat Content [Time frame: Baseline to Week 12]
  • Change in Liver Stiffness [Time frame: Baseline to Week 12]

Eligibility criteria

Inclusion criteria

  • Adults aged 18 years or older, male or female.
  • Overweight or obesity, defined as a body mass index (BMI) of 24.0-45.0 kg/m².
  • Able and willing to provide written informed consent.

Exclusion criteria

  • Active pulmonary tuberculosis, malignant tumors, human immunodeficiency virus (HIV) infection, or other severe infectious or immunocompromising conditions.
  • Severe liver injury (AST or ALT > 3 times the upper limit of normal) or severe renal dysfunction/end-stage renal disease (eGFR < 30 mL/min/1.73 m²).
  • Severe cardiovascular diseases, including angina pectoris, myocardial infarction, or stroke within the past 6 months.
  • Severe gastrointestinal disorders, or a history of gastrointestinal surgery within the past year.
  • Secondary causes of obesity, including Cushing's syndrome, primary hypothyroidism, hypothalamic obesity, acromegaly; or drug-induced obesity (e.g., antipsychotics, glucocorticoids).
  • Currently receiving other anti-obesity treatments, a previous history of bariatric surgery, or a >5% reduction in body weight within the past 3 months.
  • Current smoker or habitual smoker within the past 3 months.
  • type 1 or type 2 diabetes mellitus or currently taking hypoglycemic medications.
  • Pregnancy or planning pregnancy, or breastfeeding.
  • Unable to complete a 3-month follow-up due to health conditions or relocation.
  • Participation in any clinical study within the past 4 weeks.
  • Other conditions considered by investigators as unsuitable for participation.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
N/A
Model
Single group
Masking
Open label
Primary purpose
Treatment

Study locations

China · 1 center
  • Zhongshan Hospital, Fudan University — Shanghai

Identifiers

NCT: NCT07241533 · B2025-710

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗